Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
Open Access
- 25 July 2012
- journal article
- Published by Springer Nature in Molecular Cancer
- Vol. 11 (1) , 47
Abstract
Successful treatment of solid tumors relies on the ability of drugs to penetrate into the tumor tissue.Keywords
This publication has 29 references indexed in Scilit:
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Pharmacokinetic Considerations for New Targeted TherapiesClinical Pharmacology & Therapeutics, 2008
- Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for DegradationDevelopmental Cell, 2008
- Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100British Journal of Cancer, 2008
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)The Oncologist, 2005
- The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumorsSeminars in Oncology, 2003
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001
- The EGFR family and its ligands in human cancerEuropean Journal of Cancer, 2001